

AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions and listings of claims in the application.

LISTING OF THE CLAIMS

- 1.-6. (Cancelled).
7. (Previously Presented) A method of treating a patient suffering from breast cancer according to claim 28 comprising administering to the patient an effective amount of a chemotherapeutic agent selected from the group consisting of paclitaxel and letrozole; followed sequentially by an effective amount of 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt thereof.
- 8.-10. (Cancelled).
11. (Original) A method according to claim 7 wherein the chemotherapeutic agent is paclitaxel.
12. (Previously Presented) A method according to claim 7 wherein the chemotherapeutic agent is letrozole.
13. (Previously Presented) A method of treating a patient suffering from breast cancer according to claim 28 comprising administering to the patient an effective amount of 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or pharmaceutically acceptable salt thereof, followed sequentially by an effective amount of TNF-related apoptosis inducing ligand.
- 14.-25. (Cancelled).
26. (Currently Amended) A commercial package comprising a unit dosage form of 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof, and a unit dosage form of a chemotherapeutic agent selected from the group consisting of: paclitaxel, aromatase inhibitors and TNF-related apoptosis inducing ligand; together with instructions for administering sequential unit doses of said chemotherapeutic agent and said 2-

imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or pharmaceutically acceptable salt thereof for the treatment of breast cancer, wherein the administration of 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt thereof, is preceded sequentially by a chemotherapeutic agent selected from the group consisting of paclitaxel and letrozole, or followed sequentially by an effective amount of TNF-related apoptosis inducing ligand.

27. (Cancelled).

28. (Previously Presented) A method of treating a patient suffering from breast cancer comprising administering to the patient an effective amount of 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt thereof, wherein the administration of 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt thereof, is preceded sequentially by a chemotherapeutic agent selected from the group consisting of paclitaxel and letrozole, or followed sequentially by an effective amount of TNF-related apoptosis inducing ligand.